发明名称 USE OF CYCLODEXTRIN COMPLEXES CONTAINING LIPOIC ACID
摘要 The invention relates to the use of cyclodextrin complexes containing lipoic acid, said complexes consisting of at least one representative of the series of unsubstituted alpha-cyclodextrin, beta-cyclodextrin and gamma-cyclodextrin, and at least one representative of the series of racemic alpha-lipoic acid, racemic dihydrolipoic acid and the derivatives thereof, for producing a food supplement, a functional food supplement, a clinical nutrition product and/or a cosmetic preparation in the non-medical field of application. Said complex, which contains at least 20 wt. % of the cyclodextrin component, preferably in food quality, can also contain water and reaction products or secondary reaction products from the complex production, especially alpha-cyclodextrin being used. The cyclodextrin/(dihydro)liponic acid complexes can be used, preferably combined with other bioactive components, aromas and/or texturing products, and also the standard formulation auxiliary agents, to produce an agent for preventing and/or treating symptoms of an inflammatory nature and especially arthritis, damage to the liver function and especially alcohol intoxication, paraesthesiae and neuropathies, and for producing agents having cytoprotective and/or antiphlogistic and/or antinociceptive (analgesic) properties and/or properties that counteract the formation of radicals. Said complexes can also preferably be used to produce an agent for stimulating glucose metabolism and/or transport in muscles and/or lipocytes, agents for reinforcing the energy metabolism of the body and the brain, agents for increasing the endurance, capacity, attentiveness, concentration of the memory, agents for the prevention and/or treatment of diabetes Typ2, and agents for caring for at least partially keratinised parts of the body, especially the skin, hair, fingernails and toenails. The invention enables products to be obtained, which can be taken by the end consumer under improved compliance conditions in the non-medical field of indication, due to the distinctive stability of the agents.
申请公布号 EP1827413(A1) 申请公布日期 2007.09.05
申请号 EP20050769996 申请日期 2005.08.08
申请人 CARGILL, INCORPORATED 发明人 SCHUETT, WOLFGANG;PURPURA, MARTIN
分类号 A61K31/20;A23L1/30;A61K31/385;A61K47/48;A61P3/10;A61P19/02;A61P29/00 主分类号 A61K31/20
代理机构 代理人
主权项
地址